



PRESS RELEASE

CONTACT:

Darien Sutton

215-898-3988 | dsutton@wistar.org

The Wistar Institute Appoints Joshua Friedman, M.D., Ph.D., to its Board of Trustees

PHILADELPHIA — (May 28, 2025) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joshua Friedman, M.D., Ph.D., to its Board of Trustees. Dr. Friedman is currently Senior Vice President of Clinical Development at Spyre Therapeutics, a Massachusetts-based developer of next generation therapeutics for people living with Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

Dr. Friedman has an extensive history in drug discovery, translational science, and early and late-stage clinical development, including roles at Janssen Research and Development, Alnylam Pharmaceuticals, and Spark Therapeutics. He completed his Ph.D. research at The Wistar Institute and the University of Pennsylvania.

"I've seen first-hand the commitment to excellence and the devotion to collaborative science that are vital components of Wistar's culture," said Dr. Friedman. "Fundamental biomedical research is the bedrock of future treatments and cures, and without this type of work, there is no meaningful path toward discoveries that can change the future of human health. I'm honored to have the opportunity to lend my background and expertise to help guide the future direction of the organization."

"It's a pleasure to welcome Josh back inside The Wistar Institute," said Dario C. Altieri Ph.D., Wistar Institute president and CEO, director of the Ellen and Ronald Caplan Cancer Center, and Robert and



THE WISTAR INSTITUTE
3601 SPRUCE STREET, PHILADELPHIA, PA 19104
215-898-3700 | WISTAR.ORG



Penny Fox Distinguished Professor. “His connection to Wistar and his deep understanding of our culture and the vital work that we do, are tremendous assets for our Board and the Institution.”

Dr. Friedman received his A.B. in biochemistry from Harvard University and M.D. and Ph.D. degrees from the University of Pennsylvania School of Medicine. He completed training in Pediatrics and Pediatric Gastroenterology at the Children’s Hospital of Philadelphia and was an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine prior to moving to the pharmaceutical industry.

ABOUT THE WISTAR INSTITUTE

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a highly enabled culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org.